Editorial Disclaimer
past100 is an independent research publication. Content is for informational and educational purposes only and does not constitute medical advice. Evidence ratings reflect the strength of available peer-reviewed research — not personal recommendations. Read our methodology. Always consult a qualified healthcare provider before making any changes to your health practices.
The Opening
What if the reason you age isn't one thing, but twelve interconnected processes all degrading simultaneously? In 2013, López-Otín and colleagues published what became the most cited framework in aging biology: the Hallmarks of Aging. Updated in 2023 to include three new hallmarks, the framework describes the cellular and molecular mechanisms that drive aging across all species studied to date. Understanding the hallmarks is the prerequisite for understanding almost every intervention discussed in longevity research.
Paper of the Week
Hallmarks of aging: An integrative framework
Cell · 2023 · López-Otín et al.
The original Hallmarks paper defined nine hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. The 2023 update added three new hallmarks: dysbiosis, chronic inflammation, and disabled macroautophagy. Together, they provide a framework for understanding aging and identifying intervention targets.
Evidence Roundup
- TAME metformin trial receives FDA feedback — phase 3 design in discussion
- New study links NAD+ decline to mitochondrial dysfunction in humans
- Altos Labs announces $3B funding round for cellular reprogramming
Deep Dive
The 2023 Hallmarks of Aging update represents a watershed moment for longevity science. For the first time, we have a unified framework that explains not just what aging is, but potentially how to intervene in all twelve processes simultaneously.
The original nine hallmarks identified in 2013 have served as the roadmap for most longevity interventions over the past decade. Rapamycin targets mTOR (deregulated nutrient sensing). Metformin influences mitochondrial function. Senolytics attack cellular senescence. But the 2023 update adds three new targets that may be even more actionable:
**Dysbiosis** — The gut microbiome changes with age, losing diversity and becoming pro-inflammatory. This isn't just a correlation; the microbiome actively contributes to aging through metabolic byproducts that circulate systemically. Interventions under study: fecal microbiota transplantation, precision probiotics, prebiotics.
**Chronic Inflammation** — Aging isn't just about accumulating damage; it's about the immune system becoming perpetually activated at low levels, creating a constant inflammatory state. This "inflammaging" accelerates every other hallmark. Research areas: anti-inflammatory compounds (aspirin, colchicine), lifestyle modalities (fasting, exercise) — all currently the subject of ongoing trials.
**Disabled Macroautophagy** — The cells' recycling system breaks down with age. Proteins and organelles accumulate as toxic aggregates. Autophagy activation via compounds like rapamycin, spermidine, or urolithin A has become one of the most actively researched intervention strategies.
The key insight: these twelve hallmarks are interconnected. Improving one may improve others. This is why single-target approaches show limited effects in most trials — multi-target approaches are increasingly the direction of the field.
The most evidence-supported hallmarks for current intervention research are: 1. Cellular senescence — Senolytics are in human trials 2. Dysbiosis — FMT research is active across multiple disease contexts 3. Disabled autophagy — Exercise and fasting show consistent effects in human studies
The Verdict
Evidence Status
The Hallmarks framework is the closest thing we have to a unified theory of aging. Every major longevity intervention under study — metformin, rapamycin, senolytics — maps onto one or more of these twelve hallmarks.
What does the current evidence support?
1. The strongest evidence currently points to lifestyle interventions (structured exercise, dietary restriction protocols) as multi-hallmark approaches with the most consistent human data.
2. The evidence base for metformin as a longevity intervention consists of the ongoing TAME trial (phase 3 design under FDA review) and extensive observational data in diabetic populations — human trial results are expected in the next several years.
3. Senolytic compounds are in early-phase human trials; current human evidence is limited to small pilot studies in specific disease contexts; broader longevity evidence is not yet established.
4. Supplements targeting telomere elongation lack replicated human RCT support; telomere length as a longevity biomarker remains contested in the literature.
The framework tells us: aging is twelve simultaneous processes. Single-target approaches have limited effect sizes in most trials. The field is moving toward multi-modal intervention strategies.